Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hybrid DC Vaccine for Glioblastoma
NCT06749925Phase 3Not yet recruiting
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of dendritoma vaccine in glioblastoma (GBM) (3 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoint: Overall Survival at 2 years. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dendritoma vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06749925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749925.